[go: up one dir, main page]

EP2098591A1 - Hybridoma capable of producing anti-dectin-1 monoclonal antibody - Google Patents

Hybridoma capable of producing anti-dectin-1 monoclonal antibody Download PDF

Info

Publication number
EP2098591A1
EP2098591A1 EP09158699A EP09158699A EP2098591A1 EP 2098591 A1 EP2098591 A1 EP 2098591A1 EP 09158699 A EP09158699 A EP 09158699A EP 09158699 A EP09158699 A EP 09158699A EP 2098591 A1 EP2098591 A1 EP 2098591A1
Authority
EP
European Patent Office
Prior art keywords
dectin
present
hybridoma
antibody
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09158699A
Other languages
German (de)
French (fr)
Other versions
EP2098591B1 (en
Inventor
Yoshiyuki Adachi
Naohito Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Publication of EP2098591A1 publication Critical patent/EP2098591A1/en
Application granted granted Critical
Publication of EP2098591B1 publication Critical patent/EP2098591B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72

Definitions

  • the present invention relates to a novel hybridoma capable of producing a monoclonal antibody against dectin-1 and the like.
  • Dectin-1 is a specific receptor for (1 ⁇ 3)- ⁇ -D-glucans and present on the cell surface of leukocytes such as neutrophil, macrophage and dendritic cell (cf., Non-patent references 1 and 2).
  • Non-patent reference 3 an antiserum for dectin-1 has been reported (Non-patent reference 3), but there are no reports on a monoclonal antibody for this.
  • Non-patent reference 1 Brown, G. et al., Nature, vol. 413, p. 36-37, 2001
  • Non-patent reference 2 Taylor P.R. et al., Journal of Immunology, vol. 169, p. 3876-3882, 2002
  • Non-patent reference 3 Ariizumi, K. et al., The Journal of Biological Chemistry, vol. 275, no. 26, p. 20157-20167, 2000
  • Objects of the present invention are to provide a novel hybridoma capable of producing a monoclonal antibody against dectin-1, a novel anti-dectin-1 antibody produced by the hybridoma, a novel process for producing the anti-dectin-1 antibody using the above-described hybridoma and a novel method for detecting dectin-1 using the above-described antibody.
  • the inventors of the present invention have conducted intensive studies and, as a result, provided a novel hybridoma capable of producing a monoclonal antibody against dectin-1, a novel anti-dectin-1 antibody produced by the hybridoma, a novel process for producing the anti-dectin-1 antibody using the above-described hybridoma and a novel method for detecting dectin-1 using the above-described antibody to thereby have accomplished the present invention.
  • the present invention relates to the following (1) to (6).
  • the hybridoma of the present invention is markedly useful, because it can be used as a tool that can produce an antibody against dectin-1 uniformly, massively, permanently and inexpensively.
  • the antibody of the present invention is a novel monoclonal antibody against dectin-1 and is markedly useful. Also, according to the production process of the present invention, the antibody of the present invention can be produced uniformly and in a large amount, so that this is markedly useful.
  • dectin-1 can be detected conveniently, quickly, specifically, with high sensitivity and high accuracy, and inexpensively, so that this is markedly useful.
  • the hybridoma of the present invention can be obtained by immunizing an immune animal such as rat, mouse, guinea pig, rabbit, goat, sheep, horse, pig, dog, cat or domestic fowl with dectin-1 or a partial peptide thereof as the immunogen, recovering an antibody producer cell from lymph node, spleen, peripheral blood or the like of the immunized animal, preparing hybridomas by carrying out cell fusion of the antibody producer cell with a myeloma cell of mouse, rat, guinea pig, rabbit, goat, sheep, horse, pig, dog, cat, domestic fowl or the like, and selecting a hybridoma which produces a monoclonal antibody that reacts specifically with dectin-1.
  • an immune animal such as rat, mouse, guinea pig, rabbit, goat, sheep, horse, pig, dog, cat or domestic fowl
  • dectin-1 or a partial peptide thereof as the immunogen
  • hybridoma of the present invention examples include a hybridoma having a deposit number of FERM BP-10151 (hereinafter referred to as “hybridoma-1 of the present invention”), a hybridoma having a deposit number of FERM BP-10153 (hereinafter referred to as “hybridoma-2 of the present invention”), a hybridoma having a deposit number of FERM BP-10152 (hereinafter referred to as “hybridoma-3 of the present invention”) and the like.
  • the hybridoma-1 of the present invention obtained by carrying out cell fusion of a mouse myeloma cell with a rat lymphoid cell, has been received as a microorganism having indication for identification used by the depositor "Mouse-Rat hybridoma 4B2", on October 22, 2004, as a deposit number FERM ABP-10151 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10151. Accordingly, the hybridoma of the present invention can be obtained from the depositary.
  • the hybridoma-2 of the present invention obtained by carrying out cell fusion of a mouse myeloma cell with a rat lymphoid cell, has been received as a microorganism having indication for identification used by the depositor "Mouse-Rat hybridoma RH1", on October 22, 2004, as a deposit number FERM ABP-10153 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10153. Accordingly, the hybridoma of the present invention can be obtained from the depositary.
  • the hybridoma-3 of the present invention obtained by carrying out cell fusion of a mouse myeloma cell with a rat lymphoid cell, has been received as a microorganism having indication for identification used by the depositor "Mouse-Rat hybridoma SC30", on October 22, 2004, as a deposit number FERM ABP-10152 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10152. Accordingly, the hybridoma of the present invention can be obtained from the depositary.
  • the hybridoma of the present invention can be handled in accordance with the general culturing and preservation methods and the like of antibody producer hybridomas. Regarding the details, see the item " ⁇ 3> Production process of the present invention" which is described later.
  • the hybridoma of the present invention produces the antibody of the present invention, it can be used for the production of the antibody of the present invention and the like.
  • the antibody of the present invention is a monoclonal antibody which specifically reacts with dectin-1, and is preferably an anti-dectin-1 monoclonal antibody produced by the hybridoma of the present invention.
  • Examples of the antibody of the present invention include a monoclonal antibody against dectin-1 produced by the hybridoma-1 of the present invention (hereinafter referred to as "antibody-1 of the present invention”), a monoclonal antibody against dectin-1 produced by the hybridoma-2 of the present invention (hereinafter referred to as “antibody-2 of the present invention”), a monoclonal antibody against dectin-1 produced by the hybridoma-3 of the present invention (hereinafter referred to as "antibody-3 of the present invention”) and the like.
  • the antibody-1 of the present invention is a rat immunoglobulin G2a/ ⁇ (IgG2a/ ⁇ ) which binds to dectin-1.
  • the dectin-1 to which the antibody-1 of the present invention binds is preferably derived from a mouse.
  • the antibody-2 of the present invention is a rat immunoglobulin G1/ ⁇ (IgG1/ ⁇ ) which binds to dectin-1.
  • the dectin-1 to which the antibody-2 of the present invention binds is preferably derived from a mouse.
  • the antibody-3 of the present invention is a rat immunoglobulin G2a/ ⁇ (IgG2a/ ⁇ ) which binds to dectin-1.
  • the dectin-1 to which the antibody-3 of the present invention binds is preferably derived from a mouse.
  • the antibodies 1 and 2 of the present invention are characterized in that they have activity of inhibiting binding of BG (particularly SPG or zymosan) to dectin-1. Based on this, it can be considered that the epitopes of the antibodies 1 and 2 of the present invention with BG (particularly SPG or zymosan) in the dectin-1 molecule are common to each other.
  • the antibody-3 of the present invention is characterized in that it does not inhibit binding of BG (particularly SPG or zymosan) to dectin-1. Based on this, it can be considered that the epitopes of the antibody-3 of the present invention with BG (particularly SPG or zymosan) in the dectin-1 molecule are common to each other.
  • the antibody itself produced by the hybridoma of the present invention but also a product of the antibody labeled by a conventionally known method, the antibody immobilized on an insoluble carrier, etc., and the like can also be included in the antibody of the present invention.
  • the substance which can be used for the labeling of the antibody of the present invention is not particularly limited, so long as it can be used for the labeling of general protein, and its examples include an enzyme (peroxidase, alkaline phosphatase, ⁇ -galactosidase, luciferase, acetylcholine esterase, glucose oxidase or the like), a radioisotope ( 125 I, 131 I, 3 H or the like), a fluorescence dye (Alexa Fluor (registered trademark) 488, fluorescein isothiocyanate (FITC), 7-amino-4-methylcoumarin-3-acetic acid (AMCA), dichlorotriadinylaminofluorescein (DTAF), tetramethylrodamine isothiocyanate (TRITC), Lissamine Rhodamine B, Texas Red, Phycoerythrin (PE), umbelliferone, europium, phycocyanin, tricolor, cyanin or the
  • the method for labeling the antibody with such a substance can be optionally selected from conventionally known methods suitable for respective substances, such as a glutaraldehyde method, a periodate crosslinking method, a maleimide crosslinking method, a carbodiimide method, an activated ester method and the like when labeled with an enzyme, a chloramines T method, a lactoperoxidase method and the like when labeled with a radioisotope (cf., Second Series Biochemistry Experimentation Course 2 "Chemistry of Protein (the last volume)") edited by Tokyo Kagaku Dojin (1987 ) and the like.
  • biotin when used as the labeling substance, a method using an N-hydroxy succinimide ester derivative or hydrazide derivative of biotin (cf., Avidin-Biotin Chemistry: A Handbook, p.57-63, published in 1994 by PIERCE CHEMICAL COMPANY ) and the like can be used.
  • Examples of the shape of the insoluble carrier on which an antibody produced by the hybridoma of the present invention can be immobilized include a plate (e.g., each well of a microplate or the like), a tube, beads, a membrane, a gel, a particulate solid carrier (synthetic polymer particles such as gelatin particles, kaolin particles, or a latex, or the like) and the like.
  • examples of the material of such a carrier include polystyrene, polypropylene, polyvinyl chloride, nitrocellulose, nylon, polyacrylamide, Teflon (registered trademark), polyallomer, polyethylene, glass, agarose and the like.
  • the method for immobilizing an antibody produced by the hybridoma of the present invention on such an insoluble carrier generally known methods such as a physical adsorption method, a covalent bond method and an inclusion method as immobilized enzyme preparation methods (cf., Immobilized Enzyme, 1975, published by Kodansha, pp. 9-75 ) can be applied.
  • an antibody produced by the hybridoma of the present invention is made into an Fab-containing fragment or the like by its treatment with a protease which does not degrade antigen binding site (Fab) (e.g., plasmin, pepsin, papain or the like) are also included in the antibody of the present invention.
  • Fab antigen binding site
  • examples of the Fab-containing antibody fragment include Fabc, (Fab') 2 and the like in addition to Fab.
  • the antibody of the present invention can be produced by culturing the hybridoma of the present invention, and recovering a monoclonal antibody against dectin-1 from the culture. See the item of the following " ⁇ 3> Production process of the present invention” for its details.
  • the production process of the antibody of the present invention is not limited to this, and other production process, such as a method in which it is produced by a genetic engineering means based on the base sequence information of a gene encoding the antibody of the present invention or the amino acid sequence information of the antibody of the present invention, and the like may be employed.
  • the antibody of the present invention may be in the completely purified state, partially purified state or unpurified state.
  • Whether or not the produced antibody binds to dectin-1, or specifically binds thereto, and the like can be easily determined by those skilled in the art by general methods using dectin-1, other substance which becomes the antigen (e.g., other kind of protein) and the like.
  • the antibody of the present invention when the antibody of the present invention is preserved, distributed, used, for example, other components may be contained therein, so long as the function and activity of the antibody of the present invention are not substantially spoiled.
  • excipients, buffers, stabilizers, preservatives and the like which are generally used in preparing reagents can be contained therein.
  • Such components include, for example, phosphate buffered saline (PBS), sodium azide (NaN 3 ), bovine serum albumin (BSA) and the like.
  • the antibody of the present invention can be used for the detection, measurement and affinity purification of dectin-1 and other purposes.
  • the production process of the present invention is a process for producing a monoclonal antibody against dectin-1, which comprises culturing the hybridoma of the present invention and recovering the monoclonal antibody against dectin-1 from the culture.
  • the hybridoma of the present invention is as described above.
  • hybridoma of the present invention can be cultured in a liquid medium in which about 10% of fetal bovine serum or the like is contained in a medium generally used for the culturing of a hybridoma (e.g., RPMI 1640 (manufactured by Sigma) or the like).
  • a medium generally used for the culturing of a hybridoma e.g., RPMI 1640 (manufactured by Sigma) or the like.
  • antibiotics such as gentamicin may be further contained.
  • the conditions in culturing the hybridoma of the present invention in such a liquid medium are not particularly limited too, so long as the hybridoma produces the antibody of the present invention, but the hybridoma of the present invention to be inoculated into the liquid medium is preferably 1 to 2 ⁇ 10 5 cells/ml or more.
  • the culturing temperature is preferably about 37°C .
  • the carbon dioxide concentration in carrying out the culturing is preferably about 5% (v/v).
  • the hybridoma of the present invention can also be cultured in the living body such as the abdominal cavity of a mouse.
  • the living body can be reared under such conditions that the living body which keeps the hybridoma of the present invention can survive.
  • the term "culture" as used in the present application means a fraction which contains the monoclonal antibody against dectin-1 produced by the hybridoma of the present invention, and the hybridoma after the culturing, the medium after the culturing, a mixture of both of them and ascites (when the hybridoma of the present invention was cultured in the living body) and the like are included therein.
  • the culture is preferably "medium after the culturing” or "ascites (when the hybridoma of the present invention was cultured in the living body)". That is, the production process of the present invention preferably further comprises, after culturing of the hybridoma of the present invention, a step of separating its culture supernatant (medium after the culturing) or ascites.
  • the method for recovering the monoclonal antibody against dectin-1 from the culture is not particularly limited, too.
  • the monoclonal antibody against dectin-1 can be recovered by collecting the culture supernatant (medium after the culturing) by centrifugation, filtration or the like.
  • the monoclonal antibody against dectin-1 can be recovered by collecting ascites or the like by a general method.
  • the cultured mixture, ascites or the like collected in this manner may be directly used as the monoclonal antibody against dectin-1, or further purified by a general antibody purification method.
  • Examples of the antibody purification method include salting out with sodium sulfate, ammonium sulfate or the like, low temperature alcohol precipitation, selective precipitation fractionation by polyethylene glycol or isoelectric point, electrophoresis, ion exchange chromatography using an ion exchanger such as a DEAE (diethylaminoethyl)-derivative or CM (carboxymethyl)-derivative, affinity chromatography using protein A or protein G, hydroxyapatite chromatography, immunoadsorbent chromatography using immobilized antigen, gel filtration, ultracentrifugation and the like. In addition, these methods may be optionally combined.
  • an ion exchanger such as a DEAE (diethylaminoethyl)-derivative or CM (carboxymethyl)-derivative
  • affinity chromatography using protein A or protein G hydroxyapatite chromatography
  • immunoadsorbent chromatography using immobilized antigen gel filtration,
  • the antibody produced by the production process of the present invention binds to dectin-1, or whether or not it specifically binds thereto, and the like can be easily determined by those skilled in the art by general methods using dectin-1, other substance which becomes the antigen (e.g., other kind of protein) and the like.
  • the detection method of the present invention is a method for detecting dectin-1, which comprises reacting the antibody of the present invention with dectin-1.
  • the term “detection” as used in the present application means to find out the substance of its object as a certain form. Accordingly, the term “detection” as used in the present application is a general idea which includes not only to find out the existence (presence or absence) of its detection object but also to quantitatively find out its detection object (to measure the detection object quantitatively).
  • the method for reacting the antibody of the present invention with dectin-1 is not particularly limited, so long as it is carried out under such conditions that the molecule of the antibody of the present invention contacts with the molecule of dectin-1, and both of them are thereby bound to each other through the antigen-antibody reaction. Example of such conditions include conditions under which both of them are mixed and incubated at from 0°C to 37°C for 15 minutes to 2 hours.
  • the antibody of the present invention to be reacted with dectin-1, or the dectin-1 to be reacted with the antibody of the present invention may be in the state of being immobilized on a solid phase or the like. Accordingly, for example, detection of dectin-1 by immunoprecipitation using the antibody of the present invention, detection of dectin-1 by Western blotting using the antibody of the present invention, detection of dectin-1 on the cell surface by flow cytometry using the antibody of the present invention and the like are included in the detection method of the present invention.
  • dectin-1 can be specifically detected even when a component and the like other than dectin-1 are contained in the sample.
  • Dectin-1 can be detected by optionally selecting a conventionally known detection means in response to the kind or the like of the label bound to the antibody of the present invention.
  • a detection means for example, when one substance of a specific binding pair (e.g., biotin) is used as the label, the other substance that specifically binds thereto (e.g., streptoavidin) conjugated with an enzyme (e.g., peroxidase or the like) is added to form the specific binding pair.
  • a specific binding pair e.g., biotin
  • an enzyme e.g., peroxidase or the like
  • the substrate of the enzyme e.g., hydrogen peroxide (when the enzyme is peroxidase)
  • a coloring substance e.g., 3,3',5,5'-tetramethylbenzidine, diaminobenzidine or the like
  • the detection is effected by measuring the degree of coloration through absorbance caused by the product of the enzyme reaction.
  • radioactivity counts when a radioisotope, a fluorescence dye or a chemiluminescence substance, for example is used as the label, methods for measuring radioactivity counts, fluorescence intensity, fluorescence polarization, luminescence intensity, etc. and the like can be exemplified.
  • dectin-1 may be detected by labeling an antibody which binds to the antibody of the present invention (secondary antibody), and by using this.
  • dectin-1 can be detected via the detection and the like of such a label.
  • qualitative detection of dectin-1 detection of the existence of dectin-1
  • the presence or absence of the detection of label can be directly used as the detection result.
  • quantitative detection of dectin-1 measurement of the concentration of dectin-1, or the like
  • absorbance, radioactivity counts, fluorescence intensity, luminescence intensity and the like can be used directly as the index of the amount of dectin-1.
  • concentration and the like of dectin-1 in the sample can also be calculated by preparing a calibration curve or relational expression in advance using a standard solution of dectin-1 having known concentration, and by using this.
  • the detection method of the present invention may further comprise other steps, so long as it comprises at least the step of reacting the antibody of the present invention with dectin-1.
  • it may further comprise not only a step in which the antibody of the present invention is allowed to react with dectin-1 and then dectin-1 is detected, but also a step in which one or both of the antibody of the present invention and dectin-1 are purified prior to their reaction, a step in which the solid phase or the like is washed after reacting the antibody of the present invention with dectin-1 and before detecting dectin-1, and the like.
  • HEK 293 cell transfectant which expresses mouse-derived dectin-1 (or a mutant thereof), and biotinylated SPG.
  • a plasmid containing a cDNA encoding the mouse-derived dectin-1 (SEQ ID NO:1; GenBank accession number AF 262985) was amplified by a reverse transcriptase PCR from the total DNA prepared from a mouse macrophage cell line RAW 264 (obtained from RIKEN Cell Bank).
  • the coding region of isoform A of this dectin-1 was inserted into a mammal expression vector p3xFLAG CMV-14 (manufactured by Sigma). This vector was converted into a linear chain and transfected into HEK 293 (obtained from Cell Resource Center for Biomedical Research, Tohoku University). Thereafter, a stable HEK 293 cell transfectant which expresses the mouse-derived dectin-1 was obtained by selecting it using a medium containing Geneticin (manufactured by Invitrogen).
  • An HEK 293 cell transfectant which expresses a mutant of the mouse-derived dectin-1 was produced in the following manner.
  • a plasmid of an amino acid-mutated dectin-1 mutant was constructed in the following manner by a PCR-mediated mutagenesis using KOD-Plus DNA polymerase (manufactured by TOYOBO) and DpnI nuclease (manufactured by Roche). Forward and reverse mutant oligonucleotide primers each containing 30 bases (manufactured by Sigma Genosys) were designed by replacing its 14th and/or 15th nucleotide residue by Ala code.
  • An expression plasmid vector into which a wild type dectin-1 cDNA was inserted was faithfully reproduced by PCR using a KOD-Plus DNA polymerase and the above-described mutant oligonucleotide primers.
  • the wild type dectin-1 cDNA was digested by incubating the template plasmid in the thus obtained PCR mixture at 37°C for 3 hours in the presence of DpnI nuclease.
  • the sense and antisense DNAs were mixed and transformed into Escherichia coli DH5 ⁇ competent cells. DNA sequence of the plasmid having a mutation was confirmed using a DNA sequencer (ABI PRISM 310).
  • this cDNA having a mutation was inserted into the p3xFLAG CMV-14 vector, followed by transduction into the HEK 293 cell (10 5 cells/well) by lipofection using FuGene 6 (manufactured by Roche).
  • SPG was purchased from Kaken Pharmaceutical Co. Regarding the preparation of biotinylated SPG, it was prepared by the method described in Biol. Pharm. Bull., 17, 1508-1512 (1994 ).
  • a soluble CRD of mouse-derived dectin-1 (sCRD; a peptide moiety which corresponds to the amino acids at position 119 to 244 in SEQ ID NO:2) was prepared from a culture supernatant of a CHO-dhfr - transfectant (American Type Culture Collection). This cell line was prepared by electroporation using an expression vector containing a cDNA encoding the dectin-1 CRD and mouse dehydrofolate reductase.
  • lymphocytes were collected by incising lymph node, fused with P3X63.Ag8.653 myeloma (obtained from Cell Resource Center for Biomedical Research, Tohoku University) and cultured under hypoxanthine, aminopterin and thymidine selection conditions.
  • a hybridoma clone 4B2 which produces a rat immunoglobulin G2a/ ⁇ (IgG2a/ ⁇ ) was obtained by carrying out selection of hybridoma by selecting a culture supernatant having activity of inhibiting binding of 5 ⁇ g/ml of biotinylated SPG and 2,000-fold diluted streptoavidin-linked peroxidase (manufactured by Pharmingen) to sCRD present on the microplate.
  • This hybridoma clone (Mouse-Rat hybridoma 4B2) has been received on October 22, 2004, as a deposit number FERM ABP-10151 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10151.
  • this hybridoma clone and the antibody produced thereby are simply referred to as "4B2".
  • Transient transfectants (3 ⁇ 10 5 cells) which express various mutant dectin-1 on the HEK 293 cell (obtained from Cell Resource Center for Biomedical Research, Tohoku University) were incubated on ice for 30 minutes in the presence of 4B2 or anti-FLAG BIO-M2 antibody (10 ⁇ g/ml; manufactured by Sigma). After washing the cells, biotinylated anti-rat IgG antibody (2.5 ⁇ g/ml) and streptoavidin-Alexa 488 (5 ⁇ g/ml; manufactured by Molecular Probes) were added thereto, followed by incubation on ice for 30 minutes. The resulting cells were washed, immobilized and analyzed by FACS. The results are shown in Fig. 1 . The ordinate in respective histograms in Fig. 1 shows the number of cells, and the abscissa shows fluorescence intensity.
  • the graph of the uppermost row in Fig. 1 is a histogram respectively showing a result in which the HEK 293 cell transfected with a control vector was stained with 4B2, a result in which the HEK 293 cell transfected with wild type dectin-1 was stained with a control antibody, and a result in which the HEK 293 cell transfected with wild type dectin-1 was stained with 4B2.
  • fluorescence intensity of the former two cases was low, while fluorescence intensity of the latter one was high. It was also shown from this result that 4B2 binds to the mouse-derived wild type dectin-1.
  • FIG. 1 Also shown in Fig. 1 is a result of using HEK 293 cells respectively expressing "V220A” in which valine at position 220 in the dectin-1 molecule was mutated into alanine, "W221A” in which tryptophan at position 221 in the dectin-1 molecule was mutated into alanine, "I222A” in which isoleucine at position 222 was mutated into alanine, "H223A” in which histidine at positino 223 was mutated into alanine, and "G224A” in which glycine at position 224 was mutated into alanine.
  • the staining with 4B2 was blocked in "W221A”.
  • the staining with 4B2 was also blocked in "W221A/1222A", “I222A/H223A” and “W221A/H223A” in the same manner.
  • the staining with 4B2 was slightly blocked also in “I222A” and "H223A”, but reduction of the staining with 4B2 was not found in the case of "V220A" and "G224A". From these results, it was shown that at least tryptophan at position 221 and its peripheral amino acid residues are essential for the binding of the 4B2 to dectin-1.
  • a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of 1 mg/ml of SPG (available from Kaken Pharmaceutical Co.). Thereafter, a culture supernatant of 4B2 was added thereto, followed by incubation on ice for 30 minutes. Thereafter, the cells were washed, and the resulting cells were stained using biotinylated anti-rat IgG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of 4B2 to the SPG-treated transfectant was considerably decreased in comparison with the case in which the SPG treatment was not carried out. Contrary to this, when stained with streptoavidin-Alexa 488 using anti-FLAG BIO-M2 antibody instead of 4B2, the binding of anti-FLAG BIO-M2 antibody to the SPG-treated transfectant was not decreased.
  • a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of 4B2. Thereafter, the cells were washed, and the resulting cells were stained using 1 ⁇ g/ml or 5 ⁇ g/ml of biotinylated SPG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of the biotinylated SPG to the 4B2-treated transfectant was considerably decreased in comparison with the case in which the 4B2 treatment was not carried out.
  • hybridomas was selected to obtain a hybridoma clone RH1 which produces a rat immunoglobulin G1/ ⁇ (IgG1/ ⁇ ).
  • This hybridoma clone (Mouse-Rat hybridoma RH1) has been received on October 22, 2004, as a deposit number FERM ABP-10153 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10153.
  • this hybridoma clone and the antibody produced thereby are simply referred to as "RH1".
  • Transfectants (3 ⁇ 10 5 cells) which express dectin-1 on the HEK 293 cell (obtained from Cell Resource Center for Biomedical Research, Tohoku University) were incubated on ice for 30 minutes in the presence of RH1 or anti-FLAG BIO-M2 antibody (10 ⁇ g/ml; manufactured by Sigma). After washing the cells, biotinylated anti-rat IgG antibody (2.5 ⁇ g/ml) and streptoavidin-Alexa 488 (5 ⁇ g/ml; manufactured by Molecular Probes) were added thereto, followed by incubation on ice for 30 minutes. The resulting cells were washed, immobilized and analyzed by FACS.
  • a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of I mg/ml of SPG (available from Kaken Pharmaceutical Co.). Thereafter, a culture supernatant of RH1 was added thereto, followed by incubation on ice for 30 minutes. Thereafter, the cells were washed, and the resulting cells were stained using biotinylated anti-rat IgG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of RH1 to the SPG-treated transfectant was considerably decreased in comparison with the case in which the SPG treatment was not carried out. Contrary to this, when stained with streptoavidin-Alexa 488 using anti-FLAG BIO-M2 antibody instead of RH1, the binding of anti-FLAG BIO-M2 antibody to the SPG-treated transfectant was not decreased.
  • a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of RH1. Thereafter, the cells were washed, and the resulting cells were stained using 1 ⁇ g/ml or 5 ⁇ g/ml of biotinylated SPG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of the biotinylated SPG to the RHI-treated transfectant was considerably decreased in comparison with the case in which the RH1 treatment was not carried out.
  • hybridomas was selected to obtain a hybridoma clone SC30 which produces a rat immunoglobulin G2a/ ⁇ (IgG2a/ ⁇ ).
  • This hybridoma clone (Mouse-Rat hybridoma SC30) has been received on October 22, 2004, as a deposit number FERM ABP-10152 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10152.
  • this hybridoma clone and the antibody produced thereby are simply referred to as "SC30".
  • Transfectants (3 ⁇ 10 5 cells) which express dectin-1 on the HEK 293 cell (obtained from Cell Resource Center for Biomedical Research, Tohoku University) were incubated on ice for 30 minutes in the presence of SC30 or anti-FLAG BIO-M2 antibody (10 ⁇ g/ml; manufactured by Sigma). After washing the cells, biotinylated anti-rat IgG antibody (2.5 ⁇ g/ml) and streptoavidin-Alexa 488 (5 ⁇ g/ml; manufactured by Molecular Probes) were added thereto, followed by incubation on ice for 30 minutes. The resulting cells were washed, immobilized and analyzed by FACS.
  • a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of 1 mg/ml of SPG (available from Kaken Pharmaceutical Co.). Thereafter, a culture supernatant of SC30 was added thereto, followed by incubation on ice for 30 minutes. Thereafter, the cells were washed, and the resulting cells were stained using biotinylated anti-rat IgG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of SC30 to the SPG-treated transfectant was not decreased in comparison with the case in which the SPG treatment was not carried out. This was the same when stained with streptoavidin-Alexa 488 using anti-FLAG BIO-M2 antibody instead of SC30.
  • a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of SC30. Thereafter, the cells were washed, and the resulting cells were stained using 1 ⁇ g/ml or 5 ⁇ g/ml of biotinylated SPG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of the biotinylated SPG to the SC30-treated transfectant was not decreased in comparison with the case in which the SC30 treatment was not carried out.
  • the hybridoma of the present invention can be used as a production tool of an antibody against dectin-1.
  • the antibody of the present invention can be used in the detection, measurement, affinity purification of dectin-1 and other applications.
  • the production process of the present invention can be used in the production of the antibody of the present invention.
  • the detection method of the present invention can be used in the convenient and quick detection of pectin-1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A hybridoma capable of producing a monoclonal antibody against pectin-1, and a monoclonal antibody which specifically reacts with dectin-1.

Description

    TECHNICAL FIELD
  • The present invention relates to a novel hybridoma capable of producing a monoclonal antibody against dectin-1 and the like.
    • BACKGROUND ART
  • Firstly, the abbreviations used in the present application are described.
    • BG:
    (1→3)-β-D-glucan
    CRD:
    Carbohydrate recognition domain
    FACS:
    Fluorescence-activated cell sorter
    PBS:
    Phosphate-buffered saline
    PCR:
    Polymerase chain reaction
    SDS-PAGE:
    Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
    SPG:
    Schizophyllan (1,6-branched BG having a triple helix structure, derived from Schizophyllum commune)
  • Dectin-1 is a specific receptor for (1→3)-β-D-glucans and present on the cell surface of leukocytes such as neutrophil, macrophage and dendritic cell (cf., Non-patent references 1 and 2).
  • Conventionally, an antiserum for dectin-1 has been reported (Non-patent reference 3), but there are no reports on a monoclonal antibody for this.
    Non-patent reference 1: Brown, G. et al., Nature, vol. 413, p. 36-37, 2001
    Non-patent reference 2: Taylor P.R. et al., Journal of Immunology, vol. 169, p. 3876-3882, 2002
    Non-patent reference 3: Ariizumi, K. et al., The Journal of Biological Chemistry, vol. 275, no. 26, p. 20157-20167, 2000
    • DISCLOSURE OF THE INVENTION Problems to be solved by the invention
  • Objects of the present invention are to provide a novel hybridoma capable of producing a monoclonal antibody against dectin-1, a novel anti-dectin-1 antibody produced by the hybridoma, a novel process for producing the anti-dectin-1 antibody using the above-described hybridoma and a novel method for detecting dectin-1 using the above-described antibody.
    • Means for solving the problems
  • In order to solve the above-described problems, the inventors of the present invention have conducted intensive studies and, as a result, provided a novel hybridoma capable of producing a monoclonal antibody against dectin-1, a novel anti-dectin-1 antibody produced by the hybridoma, a novel process for producing the anti-dectin-1 antibody using the above-described hybridoma and a novel method for detecting dectin-1 using the above-described antibody to thereby have accomplished the present invention.
  • That is, the present invention relates to the following (1) to (6).
    1. (1) A hybridoma capable of producing a monoclonal antibody against dectin-1 (hereinafter referred to as "hybridoma of the present invention").
    2. (2) The hybridoma according to (1), which is a hybridoma having a deposit number of FERM BP-10151, a hybridoma having a deposit number of FERM BP-10153 or a hybridoma having a deposit number of FERM BP-10152.
    3. (3) A monoclonal antibody which specifically reacts with dectin-1.
    4. (4) A monoclonal antibody against dectin-1, which is produced by the hybridoma according to (1) or (2) (hereinafter (3) and (4) are referred to as "antibody of the present invention").
    5. (5) A process for producing a monoclonal antibody against dectin-1, which comprises culturing the hybridoma according to (1) or (2) and recovering the monoclonal antibody against dectin-1 from the culture (hereinafter referred to as "production process of the present invention").
    6. (6) A method for detecting dectin-1, which comprises reacting the monoclonal antibody according to (3) or (4) with dectin-1 (hereinafter referred to as "detection method of the present invention").
    Effect of the invention
  • The hybridoma of the present invention is markedly useful, because it can be used as a tool that can produce an antibody against dectin-1 uniformly, massively, permanently and inexpensively. The antibody of the present invention is a novel monoclonal antibody against dectin-1 and is markedly useful. Also, according to the production process of the present invention, the antibody of the present invention can be produced uniformly and in a large amount, so that this is markedly useful. In addition, according to the detection method of the present invention, dectin-1 can be detected conveniently, quickly, specifically, with high sensitivity and high accuracy, and inexpensively, so that this is markedly useful.
    • BRIEF DESCRIPTION OF THE DRAWINGS
    • Fig. 1 is a graph showing binding of 4B2 to dectin-1 or mutants thereof
    BEST MODE FOR CARRYING OUT THE INVENTION
  • The present invention is described below in detail based on the best mode for carrying out the present invention.
    • <1> Hybridoma of the present invention
  • The hybridoma of the present invention can be obtained by immunizing an immune animal such as rat, mouse, guinea pig, rabbit, goat, sheep, horse, pig, dog, cat or domestic fowl with dectin-1 or a partial peptide thereof as the immunogen, recovering an antibody producer cell from lymph node, spleen, peripheral blood or the like of the immunized animal, preparing hybridomas by carrying out cell fusion of the antibody producer cell with a myeloma cell of mouse, rat, guinea pig, rabbit, goat, sheep, horse, pig, dog, cat, domestic fowl or the like, and selecting a hybridoma which produces a monoclonal antibody that reacts specifically with dectin-1.
  • Examples of the hybridoma of the present invention include a hybridoma having a deposit number of FERM BP-10151 (hereinafter referred to as "hybridoma-1 of the present invention"), a hybridoma having a deposit number of FERM BP-10153 (hereinafter referred to as "hybridoma-2 of the present invention"), a hybridoma having a deposit number of FERM BP-10152 (hereinafter referred to as "hybridoma-3 of the present invention") and the like.
  • The hybridoma-1 of the present invention, obtained by carrying out cell fusion of a mouse myeloma cell with a rat lymphoid cell, has been received as a microorganism having indication for identification used by the depositor "Mouse-Rat hybridoma 4B2", on October 22, 2004, as a deposit number FERM ABP-10151 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10151. Accordingly, the hybridoma of the present invention can be obtained from the depositary.
  • The hybridoma-2 of the present invention, obtained by carrying out cell fusion of a mouse myeloma cell with a rat lymphoid cell, has been received as a microorganism having indication for identification used by the depositor "Mouse-Rat hybridoma RH1", on October 22, 2004, as a deposit number FERM ABP-10153 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10153. Accordingly, the hybridoma of the present invention can be obtained from the depositary.
  • The hybridoma-3 of the present invention, obtained by carrying out cell fusion of a mouse myeloma cell with a rat lymphoid cell, has been received as a microorganism having indication for identification used by the depositor "Mouse-Rat hybridoma SC30", on October 22, 2004, as a deposit number FERM ABP-10152 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10152. Accordingly, the hybridoma of the present invention can be obtained from the depositary.
  • The hybridoma of the present invention can be handled in accordance with the general culturing and preservation methods and the like of antibody producer hybridomas. Regarding the details, see the item "<3> Production process of the present invention" which is described later.
  • Since the hybridoma of the present invention produces the antibody of the present invention, it can be used for the production of the antibody of the present invention and the like.
    • <2> Antibody of the present invention
  • The antibody of the present invention is a monoclonal antibody which specifically reacts with dectin-1, and is preferably an anti-dectin-1 monoclonal antibody produced by the hybridoma of the present invention. Examples of the antibody of the present invention include a monoclonal antibody against dectin-1 produced by the hybridoma-1 of the present invention (hereinafter referred to as "antibody-1 of the present invention"), a monoclonal antibody against dectin-1 produced by the hybridoma-2 of the present invention (hereinafter referred to as "antibody-2 of the present invention"), a monoclonal antibody against dectin-1 produced by the hybridoma-3 of the present invention (hereinafter referred to as "antibody-3 of the present invention") and the like.
  • The hybridomas of the present invention are described above.
  • The antibody-1 of the present invention is a rat immunoglobulin G2a/κ (IgG2a/κ) which binds to dectin-1. The dectin-1 to which the antibody-1 of the present invention binds is preferably derived from a mouse.
  • The antibody-2 of the present invention is a rat immunoglobulin G1/κ (IgG1/κ) which binds to dectin-1. The dectin-1 to which the antibody-2 of the present invention binds is preferably derived from a mouse.
  • The antibody-3 of the present invention is a rat immunoglobulin G2a/κ (IgG2a/κ) which binds to dectin-1. The dectin-1 to which the antibody-3 of the present invention binds is preferably derived from a mouse.
  • In addition, the antibodies 1 and 2 of the present invention are characterized in that they have activity of inhibiting binding of BG (particularly SPG or zymosan) to dectin-1. Based on this, it can be considered that the epitopes of the antibodies 1 and 2 of the present invention with BG (particularly SPG or zymosan) in the dectin-1 molecule are common to each other.
  • Also, the antibody-3 of the present invention is characterized in that it does not inhibit binding of BG (particularly SPG or zymosan) to dectin-1. Based on this, it can be considered that the epitopes of the antibody-3 of the present invention with BG (particularly SPG or zymosan) in the dectin-1 molecule are common to each other.
  • In addition, it is also characterized in that at least tryptophan at position 221 in the mouse-derived dectin-1 and its peripheral amino acid residues are essential for the binding of the antibody-1 of the present invention to dectin-1.
  • Not only the antibody itself produced by the hybridoma of the present invention, but also a product of the antibody labeled by a conventionally known method, the antibody immobilized on an insoluble carrier, etc., and the like can also be included in the antibody of the present invention.
  • The substance which can be used for the labeling of the antibody of the present invention is not particularly limited, so long as it can be used for the labeling of general protein, and its examples include an enzyme (peroxidase, alkaline phosphatase, β-galactosidase, luciferase, acetylcholine esterase, glucose oxidase or the like), a radioisotope (125I, 131I, 3H or the like), a fluorescence dye (Alexa Fluor (registered trademark) 488, fluorescein isothiocyanate (FITC), 7-amino-4-methylcoumarin-3-acetic acid (AMCA), dichlorotriadinylaminofluorescein (DTAF), tetramethylrodamine isothiocyanate (TRITC), Lissamine Rhodamine B, Texas Red, Phycoerythrin (PE), umbelliferone, europium, phycocyanin, tricolor, cyanin or the like), a chemiluminescent material (luminol or the like), a hapten (dinitrofluorobenzene, adenosine monophosphate (AMP), 2,4-dinitroaniline or the like), either one part of a specific binding pair (biotin and avidins (streptoavidin or the like), lectin and a sugar chain, an agonist and a receptor of the agonist, heparin and antithrombin III (ATIII), a polysaccharide and its binding protein (hyaluronic acid and hyaluronic acid binding protein (HABP) or the like) and the like.
  • The method for labeling the antibody with such a substance can be optionally selected from conventionally known methods suitable for respective substances, such as a glutaraldehyde method, a periodate crosslinking method, a maleimide crosslinking method, a carbodiimide method, an activated ester method and the like when labeled with an enzyme, a chloramines T method, a lactoperoxidase method and the like when labeled with a radioisotope (cf., Second Series Biochemistry Experimentation Course 2 "Chemistry of Protein (the last volume)") edited by Tokyo Kagaku Dojin (1987) and the like. For example, when biotin is used as the labeling substance, a method using an N-hydroxy succinimide ester derivative or hydrazide derivative of biotin (cf., Avidin-Biotin Chemistry: A Handbook, p.57-63, published in 1994 by PIERCE CHEMICAL COMPANY) and the like can be used.
  • Examples of the shape of the insoluble carrier on which an antibody produced by the hybridoma of the present invention can be immobilized include a plate (e.g., each well of a microplate or the like), a tube, beads, a membrane, a gel, a particulate solid carrier (synthetic polymer particles such as gelatin particles, kaolin particles, or a latex, or the like) and the like. In addition, examples of the material of such a carrier include polystyrene, polypropylene, polyvinyl chloride, nitrocellulose, nylon, polyacrylamide, Teflon (registered trademark), polyallomer, polyethylene, glass, agarose and the like.
  • As the method for immobilizing an antibody produced by the hybridoma of the present invention on such an insoluble carrier, generally known methods such as a physical adsorption method, a covalent bond method and an inclusion method as immobilized enzyme preparation methods (cf., Immobilized Enzyme, 1975, published by Kodansha, pp. 9-75) can be applied.
  • In addition, those in which an antibody produced by the hybridoma of the present invention is made into an Fab-containing fragment or the like by its treatment with a protease which does not degrade antigen binding site (Fab) (e.g., plasmin, pepsin, papain or the like) are also included in the antibody of the present invention. Examples of the Fab-containing antibody fragment include Fabc, (Fab')2 and the like in addition to Fab.
  • The antibody of the present invention can be produced by culturing the hybridoma of the present invention, and recovering a monoclonal antibody against dectin-1 from the culture. See the item of the following "<3> Production process of the present invention" for its details.
  • However, the production process of the antibody of the present invention is not limited to this, and other production process, such as a method in which it is produced by a genetic engineering means based on the base sequence information of a gene encoding the antibody of the present invention or the amino acid sequence information of the antibody of the present invention, and the like may be employed.
  • In addition, the antibody of the present invention may be in the completely purified state, partially purified state or unpurified state.
  • Whether or not the produced antibody binds to dectin-1, or specifically binds thereto, and the like can be easily determined by those skilled in the art by general methods using dectin-1, other substance which becomes the antigen (e.g., other kind of protein) and the like.
  • In addition, when the antibody of the present invention is preserved, distributed, used, for example, other components may be contained therein, so long as the function and activity of the antibody of the present invention are not substantially spoiled. For example, excipients, buffers, stabilizers, preservatives and the like which are generally used in preparing reagents can be contained therein. Such components include, for example, phosphate buffered saline (PBS), sodium azide (NaN3), bovine serum albumin (BSA) and the like.
  • The antibody of the present invention can be used for the detection, measurement and affinity purification of dectin-1 and other purposes.
    • <3> Production process of the present invention
  • The production process of the present invention is a process for producing a monoclonal antibody against dectin-1, which comprises culturing the hybridoma of the present invention and recovering the monoclonal antibody against dectin-1 from the culture.
  • The hybridoma of the present invention is as described above.
  • Specific culturing method and culturing conditions for the hybridoma of the present invention are not particularly limited, so long as the hybridoma produces the antibody of the present invention. For example, the hybridoma of the present invention can be cultured in a liquid medium in which about 10% of fetal bovine serum or the like is contained in a medium generally used for the culturing of a hybridoma (e.g., RPMI 1640 (manufactured by Sigma) or the like). In this case, in order to prevent microbial contamination, antibiotics such as gentamicin may be further contained.
  • The conditions in culturing the hybridoma of the present invention in such a liquid medium are not particularly limited too, so long as the hybridoma produces the antibody of the present invention, but the hybridoma of the present invention to be inoculated into the liquid medium is preferably 1 to 2×105 cells/ml or more. Also, the culturing temperature is preferably about 37°C . In addition, the carbon dioxide concentration in carrying out the culturing is preferably about 5% (v/v).
  • In addition, the hybridoma of the present invention can also be cultured in the living body such as the abdominal cavity of a mouse. In this case, the living body can be reared under such conditions that the living body which keeps the hybridoma of the present invention can survive.
  • By culturing the hybridoma of the present invention in this manner, a monoclonal antibody against dectin-1 is produced by the hybridoma of the present invention, and the monoclonal antibody against dectin-1 is accumulated in the culture. In this connection, the term "culture" as used in the present application means a fraction which contains the monoclonal antibody against dectin-1 produced by the hybridoma of the present invention, and the hybridoma after the culturing, the medium after the culturing, a mixture of both of them and ascites (when the hybridoma of the present invention was cultured in the living body) and the like are included therein. Particularly, the culture is preferably "medium after the culturing" or "ascites (when the hybridoma of the present invention was cultured in the living body)". That is, the production process of the present invention preferably further comprises, after culturing of the hybridoma of the present invention, a step of separating its culture supernatant (medium after the culturing) or ascites.
  • The method for recovering the monoclonal antibody against dectin-1 from the culture is not particularly limited, too. For example, when the hybridoma of the present invention is cultured in a liquid medium and its culture supernatant (medium after the culturing) is used, the monoclonal antibody against dectin-1 can be recovered by collecting the culture supernatant (medium after the culturing) by centrifugation, filtration or the like. Also, when the hybridoma of the present invention was cultured in the living body, the monoclonal antibody against dectin-1 can be recovered by collecting ascites or the like by a general method.
  • The cultured mixture, ascites or the like collected in this manner may be directly used as the monoclonal antibody against dectin-1, or further purified by a general antibody purification method.
  • Examples of the antibody purification method include salting out with sodium sulfate, ammonium sulfate or the like, low temperature alcohol precipitation, selective precipitation fractionation by polyethylene glycol or isoelectric point, electrophoresis, ion exchange chromatography using an ion exchanger such as a DEAE (diethylaminoethyl)-derivative or CM (carboxymethyl)-derivative, affinity chromatography using protein A or protein G, hydroxyapatite chromatography, immunoadsorbent chromatography using immobilized antigen, gel filtration, ultracentrifugation and the like. In addition, these methods may be optionally combined.
  • Whether or not the antibody produced by the production process of the present invention binds to dectin-1, or whether or not it specifically binds thereto, and the like can be easily determined by those skilled in the art by general methods using dectin-1, other substance which becomes the antigen (e.g., other kind of protein) and the like.
    • <4> Detection method of the present invention
  • The detection method of the present invention is a method for detecting dectin-1, which comprises reacting the antibody of the present invention with dectin-1.
  • In this connection, the term "detection" as used in the present application means to find out the substance of its object as a certain form. Accordingly, the term "detection" as used in the present application is a general idea which includes not only to find out the existence (presence or absence) of its detection object but also to quantitatively find out its detection object (to measure the detection object quantitatively). The method for reacting the antibody of the present invention with dectin-1 is not particularly limited, so long as it is carried out under such conditions that the molecule of the antibody of the present invention contacts with the molecule of dectin-1, and both of them are thereby bound to each other through the antigen-antibody reaction. Example of such conditions include conditions under which both of them are mixed and incubated at from 0°C to 37°C for 15 minutes to 2 hours.
  • Also, the antibody of the present invention to be reacted with dectin-1, or the dectin-1 to be reacted with the antibody of the present invention, may be in the state of being immobilized on a solid phase or the like. Accordingly, for example, detection of dectin-1 by immunoprecipitation using the antibody of the present invention, detection of dectin-1 by Western blotting using the antibody of the present invention, detection of dectin-1 on the cell surface by flow cytometry using the antibody of the present invention and the like are included in the detection method of the present invention.
  • In addition, it is not necessary to apply treatments such as isolation and purification in advance to the dectin-1 as the detection object. That is, according to the detection method of the present invention, dectin-1 can be specifically detected even when a component and the like other than dectin-1 are contained in the sample.
  • Dectin-1 can be detected by optionally selecting a conventionally known detection means in response to the kind or the like of the label bound to the antibody of the present invention. For example, when one substance of a specific binding pair (e.g., biotin) is used as the label, the other substance that specifically binds thereto (e.g., streptoavidin) conjugated with an enzyme (e.g., peroxidase or the like) is added to form the specific binding pair. Next, the substrate of the enzyme (e.g., hydrogen peroxide (when the enzyme is peroxidase)) and a coloring substance (e.g., 3,3',5,5'-tetramethylbenzidine, diaminobenzidine or the like) are added thereto, and the detection is effected by measuring the degree of coloration through absorbance caused by the product of the enzyme reaction.
  • Also, when a radioisotope, a fluorescence dye or a chemiluminescence substance, for example is used as the label, methods for measuring radioactivity counts, fluorescence intensity, fluorescence polarization, luminescence intensity, etc. and the like can be exemplified.
  • In addition, dectin-1 may be detected by labeling an antibody which binds to the antibody of the present invention (secondary antibody), and by using this.
  • According to the detection method of the present invention, dectin-1 can be detected via the detection and the like of such a label. When qualitative detection of dectin-1 (detection of the existence of dectin-1) is desired, the presence or absence of the detection of label can be directly used as the detection result. Also, when quantitative detection of dectin-1 (measurement of the concentration of dectin-1, or the like) is desired, absorbance, radioactivity counts, fluorescence intensity, luminescence intensity and the like can be used directly as the index of the amount of dectin-1. In addition, concentration and the like of dectin-1 in the sample can also be calculated by preparing a calibration curve or relational expression in advance using a standard solution of dectin-1 having known concentration, and by using this.
  • The detection method of the present invention may further comprise other steps, so long as it comprises at least the step of reacting the antibody of the present invention with dectin-1.
  • For example, it may further comprise not only a step in which the antibody of the present invention is allowed to react with dectin-1 and then dectin-1 is detected, but also a step in which one or both of the antibody of the present invention and dectin-1 are purified prior to their reaction, a step in which the solid phase or the like is washed after reacting the antibody of the present invention with dectin-1 and before detecting dectin-1, and the like.
    • Examples
  • The present invention is described below in more detail based on Examples.
    • Reference Example
  • Firstly, preparation methods of HEK 293 cell transfectant used in the example, which expresses mouse-derived dectin-1 (or a mutant thereof), and biotinylated SPG.
    • (1) Preparation of HEK 293 cell transfectant which expresses mouse-derived dectin-1 (or a mutant thereof)
  • A plasmid containing a cDNA encoding the mouse-derived dectin-1 (SEQ ID NO:1; GenBank accession number AF 262985) was amplified by a reverse transcriptase PCR from the total DNA prepared from a mouse macrophage cell line RAW 264 (obtained from RIKEN Cell Bank). The coding region of isoform A of this dectin-1 was inserted into a mammal expression vector p3xFLAG CMV-14 (manufactured by Sigma). This vector was converted into a linear chain and transfected into HEK 293 (obtained from Cell Resource Center for Biomedical Research, Tohoku University). Thereafter, a stable HEK 293 cell transfectant which expresses the mouse-derived dectin-1 was obtained by selecting it using a medium containing Geneticin (manufactured by Invitrogen).
  • An HEK 293 cell transfectant which expresses a mutant of the mouse-derived dectin-1 was produced in the following manner.
  • A plasmid of an amino acid-mutated dectin-1 mutant was constructed in the following manner by a PCR-mediated mutagenesis using KOD-Plus DNA polymerase (manufactured by TOYOBO) and DpnI nuclease (manufactured by Roche). Forward and reverse mutant oligonucleotide primers each containing 30 bases (manufactured by Sigma Genosys) were designed by replacing its 14th and/or 15th nucleotide residue by Ala code. An expression plasmid vector into which a wild type dectin-1 cDNA was inserted was faithfully reproduced by PCR using a KOD-Plus DNA polymerase and the above-described mutant oligonucleotide primers. The wild type dectin-1 cDNA was digested by incubating the template plasmid in the thus obtained PCR mixture at 37°C for 3 hours in the presence of DpnI nuclease. The sense and antisense DNAs were mixed and transformed into Escherichia coli DH5α competent cells. DNA sequence of the plasmid having a mutation was confirmed using a DNA sequencer (ABI PRISM 310).
  • Thereafter, this cDNA having a mutation was inserted into the p3xFLAG CMV-14 vector, followed by transduction into the HEK 293 cell (105 cells/well) by lipofection using FuGene 6 (manufactured by Roche).
    • (2) Preparation of biotinylated SPG
  • SPG was purchased from Kaken Pharmaceutical Co. Regarding the preparation of biotinylated SPG, it was prepared by the method described in Biol. Pharm. Bull., 17, 1508-1512 (1994).
    • Example 1 Establishment of hybridoma (1)
  • A soluble CRD of mouse-derived dectin-1 (sCRD; a peptide moiety which corresponds to the amino acids at position 119 to 244 in SEQ ID NO:2) was prepared from a culture supernatant of a CHO-dhfr- transfectant (American Type Culture Collection). This cell line was prepared by electroporation using an expression vector containing a cDNA encoding the dectin-1 CRD and mouse dehydrofolate reductase.
  • Freund's complete adjuvant (manufactured by Difco) and sCRD were emulsified, followed by injection into the footpads of an F344 rat (obtained from Japan SLC). After completion of the third immunization, lymphocytes were collected by incising lymph node, fused with P3X63.Ag8.653 myeloma (obtained from Cell Resource Center for Biomedical Research, Tohoku University) and cultured under hypoxanthine, aminopterin and thymidine selection conditions.
  • Screening of an antibody-producing hybridoma was carried out by an enzyme-linked immunosorbent assay (ELISA) using a microplate coated with 5 µg/ml of sCRD. A hybridoma clone 4B2 which produces a rat immunoglobulin G2a/κ (IgG2a/κ) was obtained by carrying out selection of hybridoma by selecting a culture supernatant having activity of inhibiting binding of 5 µg/ml of biotinylated SPG and 2,000-fold diluted streptoavidin-linked peroxidase (manufactured by Pharmingen) to sCRD present on the microplate. This hybridoma clone (Mouse-Rat hybridoma 4B2) has been received on October 22, 2004, as a deposit number FERM ABP-10151 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10151. Hereinafter, this hybridoma clone and the antibody produced thereby are simply referred to as "4B2".
    • Example 2 Analysis of the characteristics of 4B2 (1):
  • When SDS-PAGE was carried out on the soluble mouse-derived dectin-1 under non-reducing conditions and then Western blotting was carried out using 4B2, a band was detected at the position where the soluble mouse-derived dectin-1 was present. Based on this, it was shown that 4B2 binds to the mouse-derived dectin-1.
    • Example 3 Analysis of the characteristics of 4B2 (2):
  • Transient transfectants (3×105 cells) which express various mutant dectin-1 on the HEK 293 cell (obtained from Cell Resource Center for Biomedical Research, Tohoku University) were incubated on ice for 30 minutes in the presence of 4B2 or anti-FLAG BIO-M2 antibody (10 µg/ml; manufactured by Sigma). After washing the cells, biotinylated anti-rat IgG antibody (2.5 µg/ml) and streptoavidin-Alexa 488 (5 µg/ml; manufactured by Molecular Probes) were added thereto, followed by incubation on ice for 30 minutes. The resulting cells were washed, immobilized and analyzed by FACS. The results are shown in Fig. 1. The ordinate in respective histograms in Fig. 1 shows the number of cells, and the abscissa shows fluorescence intensity.
  • The graph of the uppermost row in Fig. 1 is a histogram respectively showing a result in which the HEK 293 cell transfected with a control vector was stained with 4B2, a result in which the HEK 293 cell transfected with wild type dectin-1 was stained with a control antibody, and a result in which the HEK 293 cell transfected with wild type dectin-1 was stained with 4B2. As a result, fluorescence intensity of the former two cases was low, while fluorescence intensity of the latter one was high. It was also shown from this result that 4B2 binds to the mouse-derived wild type dectin-1.
  • Also shown in Fig. 1 is a result of using HEK 293 cells respectively expressing "V220A" in which valine at position 220 in the dectin-1 molecule was mutated into alanine, "W221A" in which tryptophan at position 221 in the dectin-1 molecule was mutated into alanine, "I222A" in which isoleucine at position 222 was mutated into alanine, "H223A" in which histidine at positino 223 was mutated into alanine, and "G224A" in which glycine at position 224 was mutated into alanine. In addition, the "W221A/I222A", "I222A/H223A" and "W221A/H223A" show the results of using HEK 293 cells respectively expressing those which have these two respective mutations in the dectin-1 molecule. The shadowed histogram shows the result of staining with 4B2.
  • As a result, the staining with 4B2 was blocked in "W221A". In addition, the staining with 4B2 was also blocked in "W221A/1222A", "I222A/H223A" and "W221A/H223A" in the same manner. The staining with 4B2 was slightly blocked also in "I222A" and "H223A", but reduction of the staining with 4B2 was not found in the case of "V220A" and "G224A". From these results, it was shown that at least tryptophan at position 221 and its peripheral amino acid residues are essential for the binding of the 4B2 to dectin-1.
    • Example 4 Analysis of the characteristics of 4B2 (3):
  • A transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of 1 mg/ml of SPG (available from Kaken Pharmaceutical Co.). Thereafter, a culture supernatant of 4B2 was added thereto, followed by incubation on ice for 30 minutes. Thereafter, the cells were washed, and the resulting cells were stained using biotinylated anti-rat IgG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of 4B2 to the SPG-treated transfectant was considerably decreased in comparison with the case in which the SPG treatment was not carried out. Contrary to this, when stained with streptoavidin-Alexa 488 using anti-FLAG BIO-M2 antibody instead of 4B2, the binding of anti-FLAG BIO-M2 antibody to the SPG-treated transfectant was not decreased.
  • In addition, a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of 4B2. Thereafter, the cells were washed, and the resulting cells were stained using 1 µg/ml or 5 µg/ml of biotinylated SPG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of the biotinylated SPG to the 4B2-treated transfectant was considerably decreased in comparison with the case in which the 4B2 treatment was not carried out.
  • In addition, when dectin-1 was incubated in advance together with 4B2, the binding of dectin-1 to zymosan was inhibited depending on the concentration of 4B2.
  • Based on these results, it was suggested that the epitopes of the 4B2 and BG (SPG, zymosan or the like) in the dectin-1 molecule are common to each other.
    • Example 5 Establishment of hybridoma (2):
  • After carrying out the same operation of Example 1, hybridomas was selected to obtain a hybridoma clone RH1 which produces a rat immunoglobulin G1/κ (IgG1/κ). This hybridoma clone (Mouse-Rat hybridoma RH1) has been received on October 22, 2004, as a deposit number FERM ABP-10153 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10153. Hereinafter, this hybridoma clone and the antibody produced thereby are simply referred to as "RH1".
    • Example 6 Analysis of the characteristics of RH1 (1):
  • When SDS-PAGE was carried out on the soluble mouse-derived dectin-1 under non-reducing conditions and then Western blotting was carried out using RH1, a band was detected at the position where the soluble mouse-derived dectin-1 was present. Based on this, it was shown that RH1 binds to the mouse-derived dectin-1.
    • Example 7 Analysis of the characteristics of RH1 (2):
  • Transfectants (3 × 105 cells) which express dectin-1 on the HEK 293 cell (obtained from Cell Resource Center for Biomedical Research, Tohoku University) were incubated on ice for 30 minutes in the presence of RH1 or anti-FLAG BIO-M2 antibody (10 µg/ml; manufactured by Sigma). After washing the cells, biotinylated anti-rat IgG antibody (2.5 µg/ml) and streptoavidin-Alexa 488 (5 µg/ml; manufactured by Molecular Probes) were added thereto, followed by incubation on ice for 30 minutes. The resulting cells were washed, immobilized and analyzed by FACS.
  • As a result, the fluorescence intensity was low when anti-FLAG BIO-M2 antibody was used, while the fluorescence intensity was high when RH1 was used. It was also shown from this result that RH1 binds to the mouse-derived wild type dectin-1.
    • Example 8 Analysis of the characteristics of RH1 (3):
  • A transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of I mg/ml of SPG (available from Kaken Pharmaceutical Co.). Thereafter, a culture supernatant of RH1 was added thereto, followed by incubation on ice for 30 minutes. Thereafter, the cells were washed, and the resulting cells were stained using biotinylated anti-rat IgG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of RH1 to the SPG-treated transfectant was considerably decreased in comparison with the case in which the SPG treatment was not carried out. Contrary to this, when stained with streptoavidin-Alexa 488 using anti-FLAG BIO-M2 antibody instead of RH1, the binding of anti-FLAG BIO-M2 antibody to the SPG-treated transfectant was not decreased.
  • In addition, a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of RH1. Thereafter, the cells were washed, and the resulting cells were stained using 1 µg/ml or 5 µg/ml of biotinylated SPG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of the biotinylated SPG to the RHI-treated transfectant was considerably decreased in comparison with the case in which the RH1 treatment was not carried out.
  • In addition, when dectin-1 was incubated in advance together with RH1, the binding of dectin-1 to zymosan was inhibited depending on the concentration of RH1.
  • Based on these results, it was suggested that the epitopes of the RH1 and BG (SPG, zymosan or the like) in the dectin-1 molecule are common to each other.
    • Example 9 Establishment of hybridoma (3):
  • After carrying out the same operation of Example 1, hybridomas was selected to obtain a hybridoma clone SC30 which produces a rat immunoglobulin G2a/κ (IgG2a/κ). This hybridoma clone (Mouse-Rat hybridoma SC30) has been received on October 22, 2004, as a deposit number FERM ABP-10152 by International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, and deposited thereto as a deposit number FERM BP-10152. Hereinafter, this hybridoma clone and the antibody produced thereby are simply referred to as "SC30".
    • Example 10 Analysis of the characteristics of SC30 (1):
  • When SDS-PAGE was carried out on the soluble mouse-derived dectin-1 under non-reducing conditions and then Western blotting was carried out using SC30, a band was detected at the position where the soluble mouse-derived dectin-1 was present. Based on this, it was shown that SC30 binds to the mouse-derived dectin-1.
    • Example 11 Analysis of the characteristics of SC30 (2):
  • Transfectants (3×105 cells) which express dectin-1 on the HEK 293 cell (obtained from Cell Resource Center for Biomedical Research, Tohoku University) were incubated on ice for 30 minutes in the presence of SC30 or anti-FLAG BIO-M2 antibody (10 µg/ml; manufactured by Sigma). After washing the cells, biotinylated anti-rat IgG antibody (2.5 µg/ml) and streptoavidin-Alexa 488 (5 µg/ml; manufactured by Molecular Probes) were added thereto, followed by incubation on ice for 30 minutes. The resulting cells were washed, immobilized and analyzed by FACS.
  • As a result, the fluorescence intensity was low when anti-FLAG BIO-M2 antibody was used, while the fluorescence intensity was high when SC30 was used. It was also shown from this result that SC30 binds to the mouse-derived wild type dectin-1.
    • Example 12 Analysis of the characteristics of SC30 (3):
  • A transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of 1 mg/ml of SPG (available from Kaken Pharmaceutical Co.). Thereafter, a culture supernatant of SC30 was added thereto, followed by incubation on ice for 30 minutes. Thereafter, the cells were washed, and the resulting cells were stained using biotinylated anti-rat IgG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of SC30 to the SPG-treated transfectant was not decreased in comparison with the case in which the SPG treatment was not carried out. This was the same when stained with streptoavidin-Alexa 488 using anti-FLAG BIO-M2 antibody instead of SC30.
  • In addition, a transfectant of dectin-1 into which the FLAG tag was incorporated was incubated in advance on ice for 30 minutes in the presence of SC30. Thereafter, the cells were washed, and the resulting cells were stained using 1 µg/ml or 5 µg/ml of biotinylated SPG and streptoavidin-Alexa 488. The cells were washed, immobilized and analyzed by FACS. As a result, the binding of the biotinylated SPG to the SC30-treated transfectant was not decreased in comparison with the case in which the SC30 treatment was not carried out.
  • In addition, when dectin-1 was incubated in advance together with SC30, the binding of dectin-1 to zymosan was not influenced by the concentration of SC30.
  • Based on these results, it was suggested that the epitopes of the SC30 and BG (SPG, zymosan or the like) in the dectin-1 molecule are not common to each other.
  • While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
  • This application is based on Japanese patent application No. 2004-329795 filed on November 12, 2004 , Japanese patent application No. 2004-329796 filed on November 12, 2004 , and Japanese patent application No. 2004-329797 filed on November 12, 2004 , the entire contents of which are incorporated hereinto by reference.
    • INDUSTRIAL APPLICABILITY
  • The hybridoma of the present invention can be used as a production tool of an antibody against dectin-1. The antibody of the present invention can be used in the detection, measurement, affinity purification of dectin-1 and other applications. Also, the production process of the present invention can be used in the production of the antibody of the present invention. In addition, the detection method of the present invention can be used in the convenient and quick detection of pectin-1.
    • Preferred Embodiments
    1. 1. A hybridoma capable of producing a monoclonal antibody against dectin-1.
    2. 2. The hybridoma according to item 1, which is a hybridoma having a deposit number of FERM BP-10151, a hybridoma having a deposit number of FERM BP-10153 or a hybridoma having a deposit number of FERM BP-10152.
    3. 3. A monoclonal antibody which specifically reacts with dectin-1.
    4. 4. A monoclonal antibody against dectin-1, which is produced by the hybridoma according to item 1 or 2.
    5. 5. A process for producing a monoclonal antibody against dectin-1, which comprises culturing the hybridoma according to item 1 or 2 and recovering the monoclonal antibody against dectin-1 from the culture.
    6. 6. A method for detecting dectin-1, which comprises reacting the monoclonal antibody according to item 3 or 4 with dectin-1.
      Figure imgb0001
      Figure imgb0002
      Figure imgb0003
      Figure imgb0004
      Figure imgb0005
      Figure imgb0006
      Figure imgb0007

Claims (4)

  1. A hybridoma which is a hybridoma having a deposit number of FERM BP-10152.
  2. A monoclonal antibody against dectin-1 according to claim 1, which is produced by the hybridoma according to claim 1 or 2.
  3. A process for producing a monoclonal antibody against dectin-1, which comprises culturing the hybridoma according to claim 1 and recovering the monoclonal antibody against dectin-1 from the culture.
  4. A method for detecting dectin-1, which comprises reacting the monoclonal antibody according to claim 2 with dectin-1.
EP09158699A 2004-11-12 2005-06-30 Hybridoma capable of producing anti-dectin-1 monoclonal antibody Not-in-force EP2098591B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004329796 2004-11-12
JP2004329795 2004-11-12
JP2004329797 2004-11-12
EP05755818A EP1813668A4 (en) 2004-11-12 2005-06-30 Hybridoma capable of producing anti-dectin-1 monoclonal antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP05755818A Division EP1813668A4 (en) 2004-11-12 2005-06-30 Hybridoma capable of producing anti-dectin-1 monoclonal antibody

Publications (2)

Publication Number Publication Date
EP2098591A1 true EP2098591A1 (en) 2009-09-09
EP2098591B1 EP2098591B1 (en) 2012-09-05

Family

ID=36336316

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05755818A Withdrawn EP1813668A4 (en) 2004-11-12 2005-06-30 Hybridoma capable of producing anti-dectin-1 monoclonal antibody
EP09158699A Not-in-force EP2098591B1 (en) 2004-11-12 2005-06-30 Hybridoma capable of producing anti-dectin-1 monoclonal antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05755818A Withdrawn EP1813668A4 (en) 2004-11-12 2005-06-30 Hybridoma capable of producing anti-dectin-1 monoclonal antibody

Country Status (5)

Country Link
US (1) US7915041B2 (en)
EP (2) EP1813668A4 (en)
JP (1) JP4637856B2 (en)
CA (1) CA2587494C (en)
WO (1) WO2006051632A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008926A (en) * 2007-02-23 2009-09-14 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1.
RU2525663C1 (en) * 2013-03-04 2014-08-20 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) STRAIN OF HYBRID CULTURED ANIMAL CELLS Mus musculus 2F9-PRODUCER OF MONOCLONAL ANTIBODIES SPECIFIC FOR LYSOSTAPHIN AND INHIBITING ITS LYTIC ACTIVITY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112649D0 (en) * 2001-05-24 2001-07-18 Isis Innovation Macrophage receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Avidin-Biotin Chemistry: A Handbook", 1994, PIERCE CHEMICAL COMPANY, pages: 57 - 63
"Chemistry of Protein", 1987, article "Second Series Biochemistry Experimentation Course 2"
"Immobilized Enzyme", 1975, KODANSHA, pages: 9 - 75
ADACHI Y ET AL: "Characterization of beta-glucan recognition site on C-type lectin, dectin 1", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 72, no. 7, 1 July 2004 (2004-07-01), pages 4159 - 4171, XP002999319, ISSN: 0019-9567 *
ARIIZUMI, K. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 26, 2000, pages 20157 - 20167
BIOL. PHARM. BULL., vol. 17, 1994, pages 1508 - 1512
BROWN, G. ET AL., NATURE, vol. 413, 2001, pages 36 - 37
TAYLOR P.R. ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 3876 - 3882
WILLMENT JANET A ET AL: "The human beta-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 35, no. 5, 1 May 2005 (2005-05-01), pages 1539 - 1547, XP002412179, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
EP2098591B1 (en) 2012-09-05
CA2587494A1 (en) 2006-05-18
CA2587494C (en) 2013-02-19
EP1813668A1 (en) 2007-08-01
JPWO2006051632A1 (en) 2008-05-29
US7915041B2 (en) 2011-03-29
EP1813668A4 (en) 2008-07-16
US20090291459A1 (en) 2009-11-26
JP4637856B2 (en) 2011-02-23
WO2006051632A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
CN108508200B (en) Method for detecting CD19 CAR-expressing cells and application thereof
CA2044421C (en) Squamous cell carcinoma-like immunoreactive antigen from human female urine
EP2884277A1 (en) Pivka-ii measurement method, measurement reagent, and measurement kit
CN102232087A (en) Antibodies to modified human IGF-1/E peptides
US20200326339A1 (en) Improved methods for monitoring immune status of a subject
EP0968429A1 (en) Method and kit for determining the phenotype of a haptoglobin and use thereof
EP2098591B1 (en) Hybridoma capable of producing anti-dectin-1 monoclonal antibody
KR910002957B1 (en) Methods and reagents for quantifying pancreatic α-amylase
EP1947460B1 (en) Method of measuring ptx3 with high sensitivity
US7833726B2 (en) Antibody for assaying ADAMTS13 activity and method for assaying the activity
US6942977B1 (en) Immunoassays for determining vitamin b12, and reagents and kits therefor
CN116143931B (en) Anti-human IgM antibody and preparation method and application thereof
JPH01233370A (en) Sandwitch type immunoassay for total monoclone igg measurement
JP2008523398A (en) CD99 as a target / marker of insulin resistance
EP3916012A2 (en) Alkaline phosphatase fusion antibody and method for producing the same, and immunoassay method
EP0133540A1 (en) Receptor assays using labeled monoclonal anti-idiotypic antibodies
JPH10226700A (en) Immunoassay for detecting mia
JP3888695B2 (en) ANTIBODY TO HUMAN LECT2, CELL PRODUCING THE SAME, MEASUREMENT METHOD AND MEASUREMENT KIT
KR20080109819A (en) New analytical methods for the detection of antibodies bound to cell membrane receptors
CN116925216B (en) Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit
CN106771216B (en) Improve the method and its application of immunoreagent detection specificity
CN117088975B (en) Anti-albumin antibody, reagent and kit for detecting albumin
CN116836274B (en) Anti-serum amyloid A antibodies, reagents and kits for detecting serum amyloid A
CN116836273B (en) Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit
JP6407990B2 (en) Augrin immunoassay

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090424

AC Divisional application: reference to earlier application

Ref document number: 1813668

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100707

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1813668

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 574169

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005036044

Country of ref document: DE

Effective date: 20121031

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 574169

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120905

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Effective date: 20120926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121206

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121216

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130105

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130107

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

26N No opposition filed

Effective date: 20130606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005036044

Country of ref document: DE

Effective date: 20130606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130630

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050630

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180619

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180511

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180627

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005036044

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190630